Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of June 2021. The document serves as a transaction notification regarding a specific insider trading event rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on a single transaction involving American Depositary Shares (ADSs).
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of notional ADSs via dividend reinvestment |
| Instrument | American Depositary Shares (ADSs) |
| Price per ADS | $38.75 |
| Volume | 1,194.932 ADSs |
| Transaction Date | June 7, 2021 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a routine acquisition of shares by a Principal Director or Manager (PDMR) through an executive savings plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of a specific transaction.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Dr. H Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: The acquisition was not a direct market purchase but resulted from the reinvestment of dividends within the GSK Executive Supplemental Savings Plan.
- Valuation: The transaction occurred at a price of $38.75 per ADS on June 7, 2021.
- Scope: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.